Department of Internal Medicine, Taoyuan Armed Forces General Hospital, Taoyuan, Taiwan; Division of Infectious Disease and Tropical Medicine, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Division of Infectious Disease and Tropical Medicine, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan; Department of Internal Medicine, Zuoying Branch of Kaohsiung Armed Forces General Hospital, Kaohsiung, Taiwan.
J Microbiol Immunol Infect. 2017 Dec;50(6):879-885. doi: 10.1016/j.jmii.2016.08.008. Epub 2016 Dec 18.
Community-onset urinary tract infections (CoUTIs) are the most common bacterial infections, and a decline in antibiotic susceptibility causes many clinical challenges. Adequate empiric antibiotic treatment can decrease unnecessary hospital stays and complications, while reducing the antimicrobial resistance progression.
From October 2014 to April 2015, we retrospectively enrolled patients who were at least 18 years old and required hospitalization for CoUTIs. Demographic variables of these patients, and uropathogens and their antimicrobial susceptibilities were evaluated.
In total, 457 patients were enrolled in this study. Their mean age was 71.9 years, and 35.2% of the patients were male. Escherichia coli (54.5%) was the most common uropathogen, followed by Klebsiella pneumoniae (13.1%), Enterococcus spp. (7.1%), Pseudomonas aeruginosa (4.6%), and Proteus mirabilis (3.5%). Bacteremia was present in 25.2% of patients. Diabetes mellitus and acute kidney injury at admission were risk factors for CoUTIs with concomitant bacteremia. Among the UTI-associated bloodstream strains, E. coli (53.1%) was also the most predominant pathogen, followed by K. pneumoniae (11.3%), Staphylococcus aureus (6.1%), and P. mirabilis (4.3%). The overall susceptibility of cefazolin was 62.8%, ceftriaxone 71.4%, ceftazidime 82.8%, flomoxef 82%, cefepime 94.5%, ampicillin-sulbactam 41.6%, piperacillin-tazobactam 85%, levofloxacin 65.2%, trimethoprim-sulfamethoxazole 61.5%, imipenem 92.3%, gentamicin 76.1%, and amikacin 97.5%. Cefazolin-susceptible isolates could be found more frequently among patients who are less than 65 years of age and without diabetes mellitus, had no UTI episode in the past year, and have no bacteremia risk. Patients with nasogastric tube retention more commonly experienced antimicrobial resistance to all the third-generation cephalosporins.
Third-generation cephalosporins effectively treated CoUTIs. However, patients with nasogastric tube retention more commonly experienced cephalosporin resistance. Cefepime, imipenem, and amikacin may be used in patients with higher antimicrobial resistance. In selected patients, cefazolin may still be an adequate drug of choice for CoUTIs.
社区获得性尿路感染(CoUTIs)是最常见的细菌性感染,抗生素敏感性下降会带来许多临床挑战。经验性使用适当的抗生素治疗可以减少不必要的住院时间和并发症,同时降低抗菌药物耐药性的进展。
我们回顾性地纳入了 2014 年 10 月至 2015 年 4 月期间至少 18 岁并因 CoUTIs 住院的患者。评估了这些患者的人口统计学变量、尿病原体及其药敏情况。
本研究共纳入了 457 例患者,平均年龄为 71.9 岁,35.2%的患者为男性。大肠埃希菌(54.5%)是最常见的尿病原体,其次是肺炎克雷伯菌(13.1%)、肠球菌属(7.1%)、铜绿假单胞菌(4.6%)和奇异变形杆菌(3.5%)。25.2%的患者合并菌血症。入院时患有糖尿病和急性肾损伤是 CoUTIs 合并菌血症的危险因素。在与 UTI 相关的血流感染菌株中,大肠埃希菌(53.1%)仍然是最主要的病原体,其次是肺炎克雷伯菌(11.3%)、金黄色葡萄球菌(6.1%)和奇异变形杆菌(4.3%)。头孢唑林的总体敏感性为 62.8%,头孢曲松为 71.4%,头孢他啶为 82.8%,氟氧头孢为 82%,头孢吡肟为 94.5%,氨苄西林-舒巴坦为 41.6%,哌拉西林-他唑巴坦为 85%,左氧氟沙星为 65.2%,复方磺胺甲噁唑为 61.5%,亚胺培南为 92.3%,庆大霉素为 76.1%,阿米卡星为 97.5%。年龄小于 65 岁且无糖尿病、过去 1 年无 UTI 发作且无菌血症风险的患者中,更容易分离到头孢唑林敏感的菌株。留置鼻胃管的患者更常经历所有三代头孢菌素的耐药性。
三代头孢菌素可有效治疗 CoUTIs。然而,留置鼻胃管的患者更常出现头孢菌素耐药性。在某些情况下,头孢吡肟、亚胺培南和阿米卡星可能是治疗高耐药性患者的选择。在选择的患者中,头孢唑林可能仍然是 CoUTIs 的一种合适的治疗药物。